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A B S T R A C T
Background: Neonates, particularly those born preterm (PTB) and with low birthweight (LBW), are especially
susceptible to bacterial and fungal infections that cause an estimated 225,000 deaths annually. Iron is a vital
nutrient for the most common organisms causing septicaemia. Full-term babies elicit an immediate postnatal
hypoferremia assumed to have evolved as an innate defence. We tested whether PTB and LBW babies are
capable of the same response.
Methods: We conducted an observational study of 152 babies who were either PTB (born 32 to <37 weeks
gestational age) and/or LBW (<2500 g) (PTB/LBW) and 278 term, normal-weight babies (FTB/NBW). Blood
was sampled from the umbilical cord vein and artery, and matched venous blood samples were taken from
all neonates between 624 h after delivery. We measured haematological, iron and inﬂammatory markers.
Findings: In both PTB/LBW and FTB/NBW babies, serum iron decreased 3-fold within 12 h of delivery com-
pared to umbilical blood (7¢5 § 4¢5 vs 23¢3 § 7¢1 ng/ml, P < 0¢001, n = 425). Transferrin saturation showed a
similar decline with a consequent increase in unsaturated iron-binding capacity. C-reactive protein levels
increased over 10-fold (P < 0¢001) and hepcidin levels doubled (P < 0¢001). There was no difference in any of
these responses between PTB/LBW and FTB/NBW babies.
Interpretation: Premature or low birthweight babies are able to mount a very rapid hypoferremia that is
indistinguishable from that in normal term babies. The data suggest that this is a hepcidin-mediated
response triggered by acute inﬂammation at birth, and likely to have evolved as an innate immune response
against bacterial and fungal septicaemia.
Trial registration: clinicaltrials.gov (NCT03353051). Registration date: November 27, 2017.
Funding: Bill & Melinda Gates Foundation (OPP1152353).
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Neonatal sepsis is the third highest cause of death globally,
accounting for 225,000 deaths each year [1]. It is projected that these
numbers will increase as a consequence of the increasing global prev-
alence of antimicrobial resistance [2].
Physiological adaption to the postnatal environment in the ﬁrst
hours of life is critical for survival. At birth, babies transition from a
semi-allogeneic, protected fetal setting to a microbe-rich extrauterine
environment [3]. The initial mass bacterial colonisation of mucosa in
the digestive, respiratory and urogenital tracts, as well as the skin,
occurs during the very early neonatal period [4]. The maternal gut is
the source of the majority of transmitted bacterial strains to the neona-
tal microbiome and common strains are also seeded from the maternal
skin and the vaginal microbiome [5]. The acquisition of symbionts can
positively affect gut maturation, metabolic homeostasis and immune
function in early life and beyond [6], but pathogenic bacteria and fungi
pose an immediate risk unless contained. Adaptive immune responses
require priming in neonates, and hence innate defence mechanisms
play an important role in containment.
Similarly, just before delivery or during the intrapartum period,
babies can be infected by micro-organisms, which may lead to early-
Abbreviations: AGP, Alpha-1-acid glycoprotein; CRP, C-reactive protein; ELISA,
Enzyme-linked immunosorbent assay; EONS, Early-onset neonatal sepsis; FTB, Full-term
birth; G6PD, Glucose-6-phosphate dehydrogenase; GCP, Good Clinical Practice; IL-6,
Interleukin 6; IL-22, Interleukin 22; KGH, Kaniﬁng General Hospital; KMC, Kaniﬁng
Municipal Council; LBW, Low birthweight; MRCG, Medical Research Council Unit The
Gambia at LSHTM; NBW, Normal birthweight; PI, Principal investigator; PTB, Preterm
birth; SCC, Scientiﬁc Coordinating Committee; sTfR, Soluble transferrin receptor; TIBC,
Total iron-binding capacity; TLR, Toll-like receptor; TSAT, Transferrin saturation; UIBC,
Unbound iron-binding capacity; WHO,World Health Organisation
* Corresponding author.
E-mail address: ccerami@mrc.gm (C. Cerami).
https://doi.org/10.1016/j.ebiom.2019.102613
2352-3964/© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
EBioMedicine 52 (2020) 102613
Contents lists available at ScienceDirect
EBioMedicine
journal homepage: www.elsevier.com/locate/ebiom
onset neonatal sepsis (EONS) especially if the mother is colonised
with pathogenic bacteria [7]. Aspiration or ingestion of infected
amniotic ﬂuid in utero or infected secretions at birth are the common
routes of infection.
Iron is an important commodity in the host-pathogen battle for
resources [8]. It is a cofactor in numerous metabolic pathways that
are critical for the human host as well as most pathogens. Therefore,
systemic iron distribution is strictly regulated by the host [9]. For
many human pathogens, the acquisition of iron via a variety of
molecular mechanisms can enhance growth and virulence [8]. Indi-
viduals with chronically high iron states (e.g. haemochromatosis)
have an enhanced risk of bacterial infection [10], as well as increased
free radical redox damage [11]. Historic studies administering paren-
teral iron to Polynesian neonates infamously increased mortality
rates by promoting Escherichia coli septicemias [12], underlining the
critical role of iron in the neonatal period.
Cord blood, which has high levels of serum iron and transferrin sat-
uration [13], has frequently been used as a proxy for neonatal iron sta-
tus. However, previous work by our group and others has shown that
healthy, vaginally-delivered, full-term babies profoundly decrease
their serum iron and TSAT levels in the ﬁrst 24 h after birth; an adapta-
tion that may have evolved as an innate defence against iron-requiring
microorganisms [14]. In the current study, we hypothesised that the
greater susceptibility of preterm and low birthweight babies to neona-
tal infections might be because they are less able to elicit this defence.
We prospectively tested this in hospital-delivered Gambian neonates.
2. Participants and methods
Full details of the methods of this study can be found in the pub-
lished protocol paper [15].
2.1. Study design
This observational study recruited well, hospital-delivered neo-
nates into four different groups characterised according to birth-
weight and gestational age as shown in Fig. 1. The primary analysis
compares all babies exhibiting preterm birth (PTB), low birthweight
(LBW) or both (PTB/LBW) versus full-term (FTB), normal birthweight
(NBW) (FTB/NBW) newborns. Secondary analyses examine the PTB
+NBW, FTB+LBW and PTB+LBW groups separately.
2.2. Ethics, standards and informed consent
The study was approved by the Medical Research Council Unit The
Gambia at London School of Hygiene and Tropical Medicine (MRCG at
LSHTM) Scientiﬁc Coordinating Committee, the Joint Gambia Govern-
ment/MRCG Ethics Committee (SCC1525) and the London School of
Hygiene and Tropical Medicine Ethics Committee (Ref: 14316). The
study was conducted according to Good Clinical Practice (GCP) stand-
ards. All participants gave written, informed consent.
2.3. Study setting
Study participants were recruited from Kaniﬁng General Hospital
(formerly Serrekunda General Hospital), in the urban Kaniﬁng region
of The Gambia, West Africa.
2.4. Recruitment, screening and enrolment
In total, we planned to identify 450 healthy newly born babies dur-
ing delivery at the Kaniﬁng General Hospital Maternity Ward. After
informed consent was obtained, neonates whomet the inclusion criteria
were enrolled. For inclusion in the study, neonates were medically sta-
ble (no birth asphyxia nor signs of sepsis as judged by the study physi-
cian), 32 weeks gestational age and weighed 2000 g. Preterm babies
(PTB) were<37 completed weeks gestational age (assessed by New Bal-
lard Score [16]). Term babies (FTB) had a gestational age 37 completed
weeks. Low birthweight (LBW) was deﬁned as <2500 g in line with the
usual WHO deﬁnition. Neonates, who weighed 2500 g were deﬁned
as normal birthweight (NBW). The observational period began at deliv-
ery and lasted until the end of the 7th day of life. Data collection started
on the 5th July 2017 and ended on 1st February 2019.
Pregnant mothers were excluded from the study if they were
below the age of 18 years, had no fetal heartbeat detected upon
admission, were known to be HIV-positive, were in receipt of Myco-
bacterium tuberculosis therapy, had taken antibiotics in the last seven
days, had a blood transfusion in the last month, were suffering from
severe pre-eclampsia or antepartum haemorrhage, or were in
another research study.
Babies were excluded at the delivery stage for the following rea-
sons: major congenital malformations (not including polydactylism),
Research in context
Evidence before this study
We searched PubMed and Ovid Medline for publications that
detail hepcidin, serum iron and TSAT concentrations in umbili-
cal cord blood or venous blood taken in the neonatal period
that were published before July 1, 2019 with restriction to pub-
lications in the English language. We used the search terms
“neonate”, “hepcidin”, “TSAT” and “serum iron”. We excluded
studies on non-humans, in medically unstable neonates or
studies that did not provide details of gestational age for the
study population. We identiﬁed 28 studies on hepcidin, 23 on
TSAT and 51 on serum iron. Collectively, 63 publications con-
tained research on full-term (FTB) neonates, and 13 on prema-
ture (PTB) neonates. Many of the retrieved publications focused
on maternal-fetal iron endowment, where umbilical cord blood
was used as a proxy for early neonatal blood. Very few publica-
tions have documented iron and inﬂammatory variables in
matched umbilical and neonatal blood samples taken in the
immediate hours (024 h) after delivery. Analysis of the
retrieved publications leads to the conclusion that neonatal
hypoferremia may exist in all neonates, however the evidence
is sparse and unclear, particularly in PTB newborns.
Added value of this study
To our knowledge, this observational non-blinded study is the
ﬁrst to assess the independent effects of gestational age and
birthweight on iron and infection parameters in healthy African
newborns in the ﬁrst hours of life. Our ﬁndings conﬁrm that a
very rapid hypoferremia occurs in the early hours of postnatal
life with evidence that it is mediated by an increase in hepcidin.
Premature and low birthweight babies exhibited almost identi-
cal postnatal hypoferremic responses to full-term, normal-
weight newborns.
Implications of the available evidence
There is now clear evidence that neonates, including those with
PTB or LBW, elicit a rapid and transient hypoferremia probably
induced, at least in part, by hepcidin. The strength and consis-
tency of this effect indicates that it may have evolved as an
innate immune response designed to protect neonates from
bacterial septicemia. This suggests the possibility that a further
enhancement or prolongation of hypoferremia (for instance by
mini-hepcidins), might offer an additional tool in the armoury
against antibiotic-resistant infections in newborns.
2 J.H. Cross et al. / EBioMedicine 52 (2020) 102613
blood transfusions given to mother or neonate, severe birth asphyxia
(requiring resuscitation), neonates born via breech, vacuum or via cae-
sarean section, or a birthweight <2000 g (in order to avoid the addi-
tional burden of a blood draw in these vulnerable neonates as guided
by the Gambia Government/MRCG and LSHTM Ethics Committees).
After the delivery stage, babies were excluded following the
detection of infection or illness (information gained from a venous
bleed or review of systems). Neonates were also removed from the
study protocol, if any medication other than intramuscular vitamin K,
tetracycline eye ointment or immunisations were given. All medica-
tions given to mothers and neonates during the study period were
recorded. Mothers who delivered multiple newborns were invited to
enrol one of their neonates into the study.
2.5. Sample collection
Once the neonate was fully delivered, one-minute delayed cord
clamping was used (followingWorld Health Organisation (WHO) pol-
icy [17]). After the umbilical cord was removed and cleaned, a trained
study nurse identiﬁed the umbilical arteries and umbilical vein. Blood
was collected from each using separate blood draw equipment.
At 624 h post-delivery, recruited mothers and their neonates
were invited to a private consultation with the study research clini-
cian. Further demographic data were collected, along with a com-
plete review of systems of the mother and neonate. Anthropometric
data on the newborn was also collected at this point. Neuromuscular
and physical maturation of each neonate was assessed using the New
Ballard Score [16]. Immediately after passing the health assessment,
a venous blood draw was performed on all neonates (2 ml for PTB/
LBW neonates and 3¢5 ml for FTB/NBW neonates).
2.6. Laboratory analyses
A full haematology panel (using a Medonic M20M GP, Boule Diag-
nostics, Spanga, Sweden) and glucose-6-phosphate dehydrogenase
deﬁciency test (R&D Diagnostics Limited, Papagos, Greece) were
conducted on whole blood. Serum was separated and stored at 20 °
C prior to analysis of ferritin, iron, unsaturated iron-binding capacity
(UIBC), soluble transferrin receptor (sTfR), transferrin, c-reactive pro-
tein (CRP), haptoglobin and alpha-1-acid glycoprotein (AGP) using a
fully automated biochemistry analyser (Cobas Integra 400 plus,
Roche Diagnostic, Switzerland). Transferrin saturation (TSAT) was
calculated. Serum samples were assessed for hepcidin concentration
by ELISA (hepcidin-25 (human) EIA Kit, DRG, USA) with a dynamic
range of 0¢13581 ng/ml.
In order to ensure a consistent assessment of haemolysis in all
serum samples, batches of samples were thawed before entering the
biochemistry analyser and visually scored by a single operator. A pre-
viously published specimen integrity chart for haemolysis was used
as reference [18]. Samples were scored 0 (yellow 0 g/L) to 6 (dark red
8 g/L). Samples scoring 5 were removed from the analysis.
2.7. Sample size determination
This study targeted recruitment of 50 neonates in each of the 3
groups PTB, LBW and PTB+LBW and 300 FTB/NBW newborns. Sample
size calculations for the primary outcomes of change in serum iron
and TSAT between cord and the ﬁrst neonatal samples were based on
data from a previous study [14] and are summarised in the published
protocol paper [15]. All secondary analyses are considered explor-
atory and were not subjected to a formal sample size calculation.
2.8. Statistical analysis
The primary analysis compared responses in the PTB and/or LBW
babies combined (PTB/LBW) versus FTB/NBW. Further subgroups of the
PTB/LBW group (groups A-C as summarised in Fig. 1) were also exam-
ined in the secondary analyses (see SupplementaryMaterial). For contin-
uous variables, baseline characteristics are presented asmeans (§ SD) for
normally distributed variables. All skewed data were transformed using
the ladder command in STATA. The ladder command searches a subset
of the ladder of powers for a transformation that converts the variable of
Fig. 1. Schematic diagram of all study groupings and the generation of subgroups. PTB = preterm birth, FTB = full-term birth, LBW = low birthweight and NBW = normal birth-
weight. FTB/NBW neonates are FTB + NBW. PTB/LBW neonates are FTB + LBW, PTB + NBW and PTB + LBW neonates.
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interest into a normally distributed variable. Results were conﬁrmed
graphically by the gladder command. Categorical variables are reported
as proportions. The rate of missing data was small (<5%), thus we did
not impute missing data. Participant characteristics and iron status indi-
cators were compared using 2-tailed t-tests or x2 tests. Multiple regres-
sion was used to explore relationships between iron status indicators,
participant characteristics, inﬂammatory and haematology markers. The
relative strength of associations was assessed using standardised coefﬁ-
cients, which represent the effect on the outcome variable (expressed as
a fraction of a standard deviation) caused by a one standard deviation
difference in the predictor variable. Changes between cord and postnatal
blood samples were assessed by paired t-tests. Comparisons of continu-
ous variables between groups A-Dwere produced using repeatmeasures
one-way analysis of variance. We examined the association between
covariates and the three outcomes iron, TSAT and hepcidin status using
linear regression models with backward elimination for variable selec-
tion. All models were adjusted for baseline (cord blood) levels. Unless
otherwise stated, all hypothesis tests were two-sided at signiﬁcance level
of 0.05. All analyses were performed using DataDesk (Data Description
Inc., Ithaca, USA) and STATA 15 (StataCorp LLC, Texas, USA).
3. Results
Fig. 2 is the CONSORT diagram summarising subject recruitment.
Baseline characteristics for the 430 neonates completing the study are
shown in Table 1. As per protocol, there was a large difference in birth-
weight between NBW (3199 § 376 g) and LBW (2338 § 118 g) new-
borns, with associated differences in length and head circumference.
Gestational age was also lower in the PTB babies (35¢6 § 0¢7) than FTB
(39¢4 § 1¢3 wk). When the LBW and PTB babies were combined as PTB/
LBW, their weight and gestational ages were signiﬁcantly lower than the
FTB/NBW newborns. Mothers of low birthweight babies were younger
(26¢8 § 6¢6 y) than FTB/NBW mothers (29¢7 § 6¢9 y), but there were no
other differences inmaternal or neonatal characteristics (Table 1 and Sup-
plementary Table 1 & 2).
3.1. Neonatal hypoferremia
Fig. 3 illustrates a profound hypoferremia occurring in the ﬁrst
day after parturition. There were no babies that failed to show a
hypoferremic response and very few in whom the response was only
moderate. Fig. 4 shows that the decline had already occurred by the
beginning of our sampling window at 6 h post-delivery. Contrary to
our initial hypothesis, there was no difference in the hypoferremic
response between any of the PTB, LBW or PTB/LBW groups and the
controls. For all the babies combined, serum iron decreased over 3-
fold from 23¢3 § 7¢1 to 7¢5 § 4¢5 mmol/L (P < 0¢001) and TSAT
decreased from 51¢7 § 17¢3 to 15¢0 § 6¢9% (P < 0¢001) (Table 2). The
mean decrease in serum iron from cord to postnatal blood was
remarkably consistent across all groups (between 15¢2 and
16¢5 mmol/L), equivalent to a range from 2¢9 to 3¢1-fold decrease
(Table 3). Likewise, the spread of the decreases in TSAT between
groups was very tight (between 35 and 39%), equivalent a 3¢3 to 3¢5-
fold reduction. Correspondingly there was a substantial increase in
UIBC in all groups indicating an enhanced ability to sequester any
free iron (22¢9 § 10¢5 to 43¢5 § 15¢9mmol/L, P < 0¢0001 for all babies
combined). Notably, ferritin, TIBC and haemoglobin levels increased
from cord to the ﬁrst neonatal bleed, and there was no change in
transferrin; thus conﬁrming that the decrease in serum iron was an
active adaptation not related to altered haemodynamics.
Fig. 5 shows that all groups had similar hepcidin levels
(20¢9 § 13¢8 in PTB/LBW vs 19¢4 § 14¢4 ng/ml in FTB/NBW) in their
cord blood. However, the cord blood from PTB neonates had slightly
higher TSAT values (54¢8 § 17¢7 vs 50¢2 § 16¢9%, P = 0¢017) and
serum iron (24¢4 § 7¢3 vs 22¢7 § 7¢0 mmol/L, P = 0¢01) in comparison
to FTB neonates. In the postnatal venous blood samples all groups
had similar hepcidin levels (37¢4 § 23¢5 in PTB/LBW vs
38¢9 § 23¢9 ng/ml in FTB/NBW). The venous blood from PTB and LBW
neonates had slightly higher TSAT values (16¢1 § 8¢4% and
16¢2 § 5¢3% vs 14¢4 § 6¢0%) in comparison to FTB neonates. There is
no evidence, that these small differences in TSAT will translate into a
Fig. 2. CONSORT diagram for participant ﬂow. PTB/LBW are displayed in GREEN, and FTB/NBW in ORANGE.
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clinically important difference in susceptibility to neonatal sepsis or
infection. Additional comparisons can be seen in Supplementary
Tables 3 & 4.
Comparisons of further iron, infection and haematological param-
eters in umbilical cord and venous blood can be seen in Supplemen-
tary Table 5. Analysis of the babies subdivided into groups A-D is
listed in Supplementary Tables 6, 7 and 8. As anticipated, based upon
the lack of difference in hypoferremia between PTB, LBW and FTB/
NBW neonates, there were no differences between the additional
subgroupings of A-D.
3.2. Factors associated with the decline in serum iron and TSAT
CRP levels increased by over 10-fold between cord and postnatal
blood (0¢17 § 0¢6 to 2¢16 § 4¢0 mg/L, P < 0¢001) and hepcidin levels
doubled (19¢9 § 14¢2 to 38¢4 § 23¢7 ng/ml, P < 0¢001). Fig. 4 illus-
trates the timecourse of the changes.
Table 3 lists the results of regression analysis of factors associated
with Day 1 serum iron. Use of standardised coefﬁcients permits rank-
ing in order of the effect size per standard deviation of the predictor
variable. In univariate analysis CRP, hepcidin and transferrin were
most strongly associated with serum iron. Note that CRP was entered
as the reciprocal of the square root, so the direction of the coefﬁcient
is reversed (i.e. a high CRP was associated with a low serum iron).
Haptoglobin, age of mother and birthweight were also signiﬁcantly
associated with serum iron. In multivariable analysis, CRP and hepci-
din were the strongest correlates. The parallel analysis for TSAT
showed broadly similar associations (Table 3).
3.3. Factors associated with postnatal hepcidin levels
Based on the pre-hoc assumption that hepcidin orchestrates the
postnatal hypoferremia, we examined the factors associated with
neonatal hepcidin levels on Day 1 (Table 4). The strongest predictor
was time of bleed with a negative coefﬁcient. Examination of Fig. 4C
suggests that this was because hepcidin rose very fast at, or immedi-
ately after, parturition and was already starting to decline by 6 h. Fer-
ritin was positively associated with hepcidin, and serum iron was
negatively correlated. Surprisingly there was no evidence of a cross-
sectional association between hepcidin and CRP.
4. Discussion
The rapid and profound postnatal hypoferremia demonstrated in
this study closely matches our prior ﬁndings in full-term, vaginally-
delivered rural Gambian babies [14] and the results of studies else-
where [19,20]. The 3¢4-fold decrease recorded here is towards the
top end of the 24 -fold range recorded in prior studies [14,19,20].
We have previously proposed that this may represent an evolved
innate immune response designed to deprive blood-stream bacteria
of iron and hence create a hostile bacteriostatic environment [14].
The current study was designed to test the hypothesis that immature
or growth-restricted neonates might have a lesser ability to trigger
this innate defence and that this might explain their greater suscepti-
bility to septicemias [21]. Our hypothesis was ﬁrmly refuted. We
showed that the premature and low birthweight neonates all exhib-
ited a profound hypoferremia during the ﬁrst 24 h of life, with no
detectable differences from the full-term, normal birthweight new-
borns. In fact, there was a remarkable similarity in the hypoferremic
response across all the study groups that underscores the efﬁciency
of the process and supports the likelihood that it occurs by design.
The host-pathogen battle for iron has been extensively studied
[22] and it has long been assumed that the hypoferremia of the acute
phase response acts as an innate defence against iron-requiring
organisms. Hepcidin is a key, though not necessarily the only [23],
regulator of this response [24]. Inﬂammatory cytokines including IL-
6, IL-22 and Type-1 interferon rapidly upregulate hepcidin expres-
sion and release from the liver [25]. Hepcidin causes hypoferremia by
inhibiting the action of the transmembrane iron-exporter ferroportin
in enterocytes and macrophages, thus blocking iron absorption and
recycling [26]. Injection of recombinant hepcidin results in the very
rapid induction of hypoferremia in mice [27] and humans [28].
In both univariate and multivariate analysis neonatal serum iron
and TSAT levels were most strongly correlated with CRP and hepcidin
(Table 3) suggesting that the hypoferremia is, at least partly, driven
by an inﬂammatory response to the stress of the birth process and/or
Table 1
Participant characteristics.
Whole Population FTB/NBW PTB/LBW P value FTB PTB P value NBW LBW P value
Number of participants (n) 430 278 152 ¢¢ 289 141 ¢¢ 377 53 ¢¢
Characteristic Mean (§ SD)
Gestational age (Weeks) 38¢1 (§2¢1) 39¢4 (§1¢3) 35¢8 (§1¢1) <0¢001 39¢4 (§1¢3) 35¢6 (§0¢7) <0¢001 38¢4 (§2¢0) 35¢9 (§1¢7) <0¢001
Birthweight (g) 3092 (§453) 3299 (§368¢3) 2715 (§338¢5) <0¢001 3264 (§402¢2) 2741 (§336¢9) <0¢001 3199 (§376¢3) 2338 (§117¢7) <0¢001
Head circumference (cm) 34¢0 (§1¢2) 34¢6 (§1¢0) 33¢0 (§0¢1) <0¢001 34¢5 (§1¢1) 33¢1 (§0¢1) <0¢001 34¢3 (§1¢1) 32¢3 (§0¢8) <0¢001
Length (cm) 49¢2 (§1¢9) 50¢0 (§1¢6) 47¢7 (§1¢6) <0¢001 49¢9 (§1¢7) 47¢7 (§1¢6) <0¢001 49¢6 (§1¢7) 46¢7 (§1¢4) <0¢001
Maternal haemoglobin
7 days before delivery
(g/dl)
11¢6 (§1¢8) 11¢6 (§1¢8) 11¢4 (§1¢8) 0¢25 11¢6 (§1¢8) 11¢5 (§1¢8) 0¢35 11¢5 (§1¢8) 11¢8 (§1¢7) 0¢75
Age of mother (Years) 29¢4 (§6¢9) 29¢7 (§6¢9) 28¢7 (§6¢8) 0¢16 29¢6 (§7¢0) 28¢9 (§6¢8) 0¢35 29¢7 (§6¢9) 26¢8 (§6¢6) 0¢003
1 min APGAR score (010) 9¢7 (§0¢7) 9¢6 (§0¢8) 9¢7 (§0¢6) 0¢51 9¢6 (§0¢8) 9¢8 (§0¢6) 0¢26 9¢7 (§0¢7) 9¢6 (§0¢8) 0¢7
Time from admission to
birth (Hours)
3¢2 (§5¢1) 3¢2 (§5¢2) 3¢2 (§4¢8) 0¢96 3¢2 (§5¢2) 3¢2 (§4¢8) 0¢94 3¢2 (§5¢1) 3¢3 (§5¢0) 0¢94
Time from delivery to post-
natal venous blood col-
lection (Hours)
12¢7 (§5¢3) 12¢7 (§5¢4) 12¢8 (§5¢3) 0¢81 12¢6 (§5¢3) 13¢0 (§5¢3) 0¢47 12¢8 (§5¢3) 12¢5 (§4¢8) 0¢71
Percentage (%)
Percentage male (%) 53¢5% (224) 54¢3% (151) 52¢0% (79) 0¢64 54¢7% (158) 51¢1% (72) 0¢48 53¢8% (203) 50¢9% (27) 0¢69
Percentage early term,
37-38 weeks (%)
19¢3% (83) 27¢7% (77) 3¢9% (6) <0¢001 28¢7% (83) 0¢0% (0) <0¢001 20¢4% (77) 11¢3% (6) 0¢12
G6PD deﬁciency positive
(%)
12¢6% (54) 11¢5% (32) 14¢6% (22) 0¢36 11¢4% (33) 15¢0% (21) 0¢3 13¢3% (50) 7¢7% (4) 0¢26
Multiple births (%) 3% (13) 2¢2% (6) 4¢6% (7) 0¢16 2¢1% (6) 4¢9% (7) 0¢1 2¢7% (10) 5¢7% (3) 0¢23
Percentage of mothers on
antenatal iron/folic acid
(%)
82¢1% (353) 81¢7% (227) 82¢9% (126) 0¢87 81¢0% (234) 84¢4% (119) 0¢83 83¢3% (314) 73¢6% (39) 0¢1
Demographic, clinical and pregnancy outcome characteristics of the women and their newborns. Data are presented as arithmetic mean (§ SD) and analysed by one-way analysis
of variance or as a proportion (%) and analysed by Pearson x2 test. P values in bold font are considered signiﬁcant based on P < 0¢05.
J.H. Cross et al. / EBioMedicine 52 (2020) 102613 5
Fig. 3. Analysis of serum iron (A), TSAT (B) and hepcidin (C) in umbilical cord (BLUE) and postnatal venous blood (RED) based on all study groupings. Horizontal lines repre-
sent the arithmetic group means. FTB/NBW are FTB + NBW. PTB/LBW are FTB + LBW, PTB + NBW and PTB + LBW neonates. All group comparisons between cord and venous blood
are statistically signiﬁcant (P< 0¢001). Hepcidin displayed as log10.
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the exposure of the newborn to vaginal and/or gastrointestinal micro-
organisms not previously encountered in utero. The modest proportion
of variance explained in the full multivariate model (29% for serum
iron and 22% for TSAT) might reﬂect the fact that both measures have
been suppressed to close to their physiological lower limit and hence
display a limited range. It is also possible that hepcidin-independent
mechanisms, driven by effector molecules unmeasured in this study,
are playing an additional role [23]. A full examination of the mecha-
nism responsible for the hypoferremia would probably require studies
in an animal model (e.g. neonatal piglets).
Using ex vivo assays with sentinel bacteria, we have previously
demonstrated that low TSAT values in serum from adults [29] and
neonates [14] exerts a powerful bacteriostatic effect. In the neonatal
study, growth rates of Escherichia coli, Streptococcus pneumoniae,
Streptococcus agalactiae and Staphylococcus aureus, were highly sig-
niﬁcantly lower in neonatal serum than in cord serum and for each
organism growth rates were signiﬁcantly associated with TSAT. S.
aureus was least responsive, possibly reﬂecting its ability to utilise
haem iron, though it was still clearly inﬂuenced by transferrin satura-
tion. E. coli was most responsive, which may explain why intramus-
cular iron administration to Polynesian neonates increased
septicaemia rates with a major shift towards E. coli as the most fre-
quently identiﬁed cause [12]. The hypoferremia observed in the
current hospital-based study (in both PTB/LBW and FTB/NBW babies)
was more profound than we previously observed in rural home deliv-
eries [14] (TSAT declined to 15% versus 24% in rural babies) and hence
the bacteriostatic effect would be expected to be even greater.
There are several strengths and limitations to our study. The large
sample size allows us to conﬁdently exclude any clinically-meaning-
ful differences in the postnatal response of preterm and low birth-
weight babies compared to the full-term normal birthweight
neonates. By protocol, we did not recruit mothers with complex med-
ical histories (e.g. pre-eclampsia, antepartum haemorrhage or ante-
natal infection) or sick babies (e.g. with birth asphyxia or suspected
sepsis). We did not recruit newborns born<32 completed weeks ges-
tation and/or <2000 g birthweight, or those delivered via c-section,
vacuum or forceps. We cannot speculate whether similar hypoferre-
mic responses would occur in such cases, but reciprocally we can
conclude that the responses we observed are a characteristic feature
of normal human birth and were not elicited by pathological circum-
stances. In order to allow mothers to recover from their delivery and
the neonates to be stabilised and checked for inclusion, we con-
strained our ﬁrst postnatal blood draw to after 6 h post-delivery.
With many samples collected soon after this point, we have demon-
strated that the reduction in circulating iron levels occurs very rap-
idly but we cannot state how rapidly. We did not measure pro-
Fig. 4. Timecourse of the changes in serum iron (A), TSAT (B), hepcidin (C) and CRP (D) in the ﬁrst day of life.Means § 95% CI. PTB/LBW are RED columns and signiﬁcance lines.
FTB/NBW are BLUE columns and signiﬁcance lines. Columns are plotted according to mean time of bleed for the categories 0, 18, 916 and 1724 h. **** = P < 0¢0001,
*** = P < 0¢001, ** = P < 0¢01, * = P < 0¢05. No signiﬁcance line = P> 0¢05.
J.H. Cross et al. / EBioMedicine 52 (2020) 102613 7
Table 2
Iron Parameters (cord vs venous sample) for FTB/NBW, PTB/LBW, PTB and LBW neonates.
Whole Population FTB/NBW PTB/LBW Preterm Birth (PTB) Low Birthweight (LBW)
Sample Type n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value
Serum
iron
(mmol/L)
425 23¢3
(§7¢1)
421 7¢5
(§4¢5)
<0¢001 275 22¢7
(§7¢0)
271 7¢3
(§4¢6)
<0¢001 150 24¢3
(§7¢3)
150 8¢0
(§4¢1)
<0¢001 140 24¢4
(§7¢3)
139 7¢8
(§4¢1)
<0¢001 51 24¢5
(§7¢7)
51 8¢5
(§3¢4)
<0¢001
UIBC
(mmol/L)
423 22¢9
(§10¢5)
420 43¢5
(§15¢9)
<0¢001 273 23¢7
(§10¢4)
271 44¢1
(§18¢0)
<0¢001 150 21¢5
(§10¢6)
149 42¢2
(§10¢9)
<0¢001 140 21¢2
(§9¢8)
138 42¢0
(§10¢9)
<0¢001 51 22¢1
(§12¢2)
50 43¢8
(§10¢2)
<0¢001
TIBC
(mmol/L)
423 46¢1
(§8¢0)
420 51¢0
(§17¢9)
<0¢001 273 46¢3
(§8¢1)
271 51¢4
(§20¢7)
<0¢001 150 45¢8
(§7¢8)
149 50¢2
(§11¢3)
<0¢001 140 45¢6
(§7¢4)
138 49¢8
(§11¢1)
<0¢001 51 46¢6
(§9¢3)
50 52¢3
(§11¢9)
<0¢001
Transferrin
(g/L)
426 1¢96
(§0¢3)
423 1¢99
(§0¢3)
0¢003 275 1¢98
(§0¢3)
273 1¢98
(§0¢3)
0¢8335 151 1¢93
(§0¢3)
150 2¢00
(§0¢3)
<0¢001 141 1¢92
(§0¢3)
139 1¢99
(§0¢3)
<0¢001 52 1¢94
(§0¢4)
51 2¢02
(§0¢4)
0¢0024
TSAT (%) 423 51¢7
(§17¢3)
420 15¢0
(§6¢9)
<0¢001 273 50¢2
(§16¢7)
271 14¢4
(§6¢1)
<0¢001 150 54¢5
(§18¢0)
149 16¢2
(§8¢2)
<0¢001 140 54¢8
(§17¢7)
138 16¢1
(§8¢4)
<0¢001 51 54¢6
(§18¢7)
50 16¢2
(§5¢3)
<0¢001
Serum
ferritin
(ug/L)
426 210¢5
(§157¢8)
415 381¢2
(§297¢6)
<0¢001 275 212¢6
(§157¢7)
271 393¢9
(§312¢6)
<0¢001 151 206¢6
(§158¢5)
149 358¢6
(§268¢1)
<0¢001 141 206¢8
(§154¢8)
138 355¢7
(§259¢6)
<0¢001 52 192¢1
(§179¢5)
51 366¢2
(§343¢8)
<0¢001
Serum AGP
(g/L)
426 0¢18
(§0¢1)
423 0¢24
(§0¢2)
<0¢001 275 0¢19
(§0¢1)
273 0¢25
(§0¢2)
<0¢001 151 0¢17
(§0¢1)
150 0¢23
(§0¢2)
<0¢001 141 0¢16
(§0¢2)
139 0¢22
(§0¢2)
<0¢001 52 0¢16
(§0¢1)
51 0¢21
(§0¢16)
<0¢001
Serum CRP
(mg/L)
425 0¢17
(§0¢6)
422 2¢16
(§4¢0)
<0¢001 275 0¢19
(§0¢7)
273 2¢27
(§4¢1)
<0¢001 150 0¢14
(§0¢2)
149 1¢96
(§3¢8)
<0¢001 140 0¢14
(§0¢2)
138 1¢99
(§3¢9)
<0¢001 51 0¢10
(§0¢07)
51 1¢14
(§1¢8)
0¢0002
>5mg/L 2 0¢5% 54 12¢8% <0¢001 2 0¢7% 37 13¢6% <0¢001 0 0¢0% 17 11¢4% <0¢001 0 0¢0% 16 11¢6% <0¢001 0 0¢0% 4 7¢8% 0¢041
>3mg/L 3 0¢7% 83 19¢7% <0¢001 3 1¢0% 59 21¢6% <0¢001 0 0¢0% 24 16¢1% <0¢001 0 0¢0% 23 16¢7% <0¢001 0 0¢0% 6 11¢8% 0¢011
Serum
hepcidin
(ng/ml)
425 19¢9
(§14¢2)
417 38¢4
(§23¢7)
<0¢001 277 19¢4
(§14¢4)
270 38¢9
(§23¢9)
<0¢001 148 20¢9
(§13¢8)
147 37¢4
(§23¢5)
<0¢001 138 21¢5
(§13¢9)
136 37¢7
(§23¢3)
<0¢001 52 17¢6
(§13¢0)
51 33¢7
(§22¢2)
<0¢001
Haemoglobin
(g/dl)
414 15¢3
(§2¢5)
423 19¢4
(§3¢1)
<0¢001 270 15¢1
(§2¢3)
272 19¢1
(§2¢9)
<0¢001 144 15¢6
(§2¢7)
151 19¢9
(§3¢3)
<0¢001 136 15¢6
(§2¢6)
140 19¢8
(§3¢3)
<0¢001 48 16¢3
(§3¢1)
52 20¢7
(§3¢5)
<0¢001
Data are presented as mean (§ SD) and analysed by one-way analysis of variance. P values in bold font are considered signiﬁcant based on P < 0¢05. Skewed variables were transformed as follows: log10(serum iron), 1/sqrt(TIBC), sqrt (fer-
ritin), 1/sqrt(CRP), log10(hepcidin).
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inﬂammatory cytokines (e.g. IL-6 and IL-22) which might have pro-
vided additional insights into the mechanisms eliciting hypoferremia.
Similarly, we did not attempt to address any possible hepcidin-inde-
pendent mechanisms because the putative mediators remain
unknown. Such studies may require animal models.
In conclusion, our results suggest that the innate postnatal iron
restriction strategy in the ﬁrst hours of life has evolved as an intrinsic
mechanism to protect neonates from common pathogens and/or
free-radical damage, and occurs regardless of gestational age or birth-
weight. This hypoferremia is at least partly mediated by the hor-
mone, hepcidin. The trigger mechanism, relation to maternal iron
status, and its effect on susceptibility to systemic bacterial infections
require further investigation.
Our results highlight the importance of hypoferremia as a con-
served mechanism of protection, and prompt further research into
the use of iron restriction as a transient bacteriostatic mechanism to
limit bacterial growth and virulence in other instances of infection.
Hypoferremia can slow the multiplication of bacterial pathogens
[29], which in combination with antibiotics, could allow enough time
for the adaptive immune system to ﬁght the infection. Augmentation
of innate immunity in neonates and other at-risk groups (elderly or
immunocompromised) might be achieved by the use of small mole-
cule orally-administered mini-hepcidins currently under develop-
ment as hepcidin agonists [28,30].
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Table 3
Linear regression of factors associated with postnatal serum iron and TSAT.
Predictor Coefﬁcient Standard
error
Standardised
coefﬁcient
P value R2 (%)
Univariate Analysis - Serum Iron
CRPa 0¢135 0¢023 0¢258 <0¢0001 15¢5
Hepcidinb 0¢139 0¢025 0¢249 <0¢0001 14¢2
Transferrin 0¢273 0¢056 0¢222 <0¢0001 13¢7
Haptoglobin 1¢21 0¢303 0¢184 <0¢0001 12¢2
Age of mother 0¢009 0¢002 0¢152 0¢001 11¢1
Birthweight 0¢0001 0¢00,004 0¢149 0¢001 11
Multivariate Analysis - Serum Iron
CRPa 0¢124 0¢022 0¢239 <0¢0001 29¢2
Hepcidinb 0¢11 0¢025 0¢198 <0¢0001
Transferrin 0¢23 0¢055 0¢186 <0¢0001
Age of mother 0¢008 0¢002 0¢143 0¢001
Haptoglobin 0¢741 0¢28 0¢114 0¢008
Birthweight 0¢00,009 0¢00,003 0¢104 0¢016
Univariate Analysis - Transferrin Saturation (TSAT)
CRPa 0¢153 0¢023 0¢306 <0¢0001 11¢7
Haptoglobin 1¢14 0¢302 0¢181 <0¢0001 5¢7
Hepcidinb 0¢085 0¢025 0¢16 0¢001 4¢8
Birthweight 0¢0001 0¢00,004 0¢153 0¢001 4¢7
Age of mother 0¢008 0¢002 0¢151 0¢002 4¢7
Multivariate Analysis - Transferrin Saturation (TSAT)
CRPa 0¢139 0¢022 0¢285 <0¢0001 21¢8
Hepcidinb 0¢093 0¢024 0¢253 <0¢0001
Ferritin 0¢008 0¢002 0¢187 <0¢0001
Age of mother 0¢68 0¢285 0¢161 <0¢0001
All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked
according to their standardised coefﬁcients calculated in STATA.
a 1/sqrt(CRP).
b log10 (hepcidin).
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Fig. 5. Comparisions of serum iron (A = cord, B = venous), TSAT (C = cord, D = venous) and hepcidin (E = cord, F = venous) in cord and postnatal venous blood.Means § 95% CI.
FTB/NBW are BLUE columns. PTB/LBW are RED columns. PTB are DARK GREY columns. LBW are LIGHT GREY columns. Signiﬁcance lines represent the comparision of PTB/LBW , PTB
or LBW groups to the FTB/NBW group. ** = P< 0¢01, * = P< 0¢05. No signiﬁcance line = P > 0¢05.
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Table 4
Linear regression of factors associated with postnatal serum hepcidin.
Predictor Coefﬁcient Standard
error
Standardised
coefﬁcient
P value R2 (%)
Univariate analysis - Serum hepcidin
Ferritina 0¢039 0¢0005 0¢354 <0¢0001 14
Time of bleed 0¢0007 0¢0001 0¢321 <0¢0001 12
Transferrin 0¢706 0¢104 0¢318 <0¢0001 11¢5
Serum ironb 0¢479 0¢089 0¢267 <0¢0001 8¢2
sTfRc 0¢36 0¢092 0¢189 0¢001 5
Multivariate analysis - Serum hepcidin
Time of bleed 0¢0008 0¢00,009 0¢354 <0¢0001 36¢1
Ferritina 0¢035 0¢004 0¢319 <0¢0001
Serum ironb 0¢413 0¢078 0¢232 <0¢0001
sTfRc 0¢286 0¢086 0¢15 0¢001
Transferrin 0¢218 0¢111 0¢1 0¢05
All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked
according to their standardised regression coefﬁcients calculated in STATA.
a sqrt(ferritin).
b log10 (serum iron).
c sqrt(sTfR).
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